Comparative Pharmacology
Head-to-head clinical analysis: ACETAMINOPHEN AND IBUPROFEN versus DYLOJECT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAMINOPHEN AND IBUPROFEN versus DYLOJECT.
ACETAMINOPHEN AND IBUPROFEN vs DYLOJECT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
None Documented
None Documented
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Category D/X
Category C
NSAID
NSAID